Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Miki Horiguchi, Ph.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Biller LH, Horiguchi M, Uno H, Ukaegbu C, Syngal S, Yurgelun MB. Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome. Gastroenterology. 2021 07; 161(1):143-150.e4. PMID: 33794268.
    Citations:    Fields:    
  2. Mannucci A, Furniss CS, Ukaegbu C, Horiguchi M, Fehlmann T, Uno H, Yurgelun MB, Syngal S. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. J Clin Oncol. 2020 12 01; 38(34):4086-4094. PMID: 32997573.
    Citations:    Fields:    Translation:HumansCells
  3. Horiguchi M, Hassett MJ, Uno H. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology. Clin Trials. 2020 12; 17(6):597-606. PMID: 32933339.
    Citations:    Fields:    Translation:Humans
  4. Horiguchi M, Uno H. On permutation tests for comparing restricted mean survival time with small sample from randomized trials. Stat Med. 2020 09 10; 39(20):2655-2670. PMID: 32432805.
    Citations: 2     Fields:    Translation:Humans
  5. Uno H, Horiguchi M, Hassett MJ. Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist. 2020 02; 25(2):91-93. PMID: 32043795.
    Citations: 1     Fields:    Translation:Humans
  6. Horiguchi M, Hassett MJ, Uno H. How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated? Oncologist. 2019 07; 24(7):867-871. PMID: 30201741.
    Citations: 2     Fields:    Translation:Humans
  7. Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, Schrag D, Wei LJ. Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. JAMA Oncol. 2018 06 01; 4(6):881-882. PMID: 29801103.
    Citations: 2     Fields:    Translation:Humans
  8. Horiguchi M, Cronin AM, Takeuchi M, Uno H. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials. Stat Med. 2018 07 10; 37(15):2307-2320. PMID: 29682762.
    Citations: 3     Fields:    Translation:Humans
  9. Sun R, Horiguchi M, Wei LJ. Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. J Clin Oncol. 2018 05 01; 36(13):1378-1379. PMID: 29558278.
    Citations: 1     Fields:    Translation:Humans
  10. Horiguchi M, Uno H, Wei LJ. Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer. J Clin Oncol. 2018 03 10; 36(8):825-826. PMID: 29373099.
    Citations: 2     Fields:    Translation:Humans
  11. Horiguchi M, Uno H, Wei LJ. Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. J Clin Oncol. 2018 03 01; 36(7):720-721. PMID: 29337638.
    Citations: 3     Fields:    Translation:Humans
  12. Horiguchi M, Uno H, Wei LJ. Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. J Clin Oncol. 2017 10 10; 35(29):3373. PMID: 28800271.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Horiguchi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (51)
Explore
_
Co-Authors (9)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.